Acute myelomonocytic leukemia with histologic features resembling sarcomatoid carcinoma in bone marrow.
We report a case of primary acute myelomonocytic leukemia involving the bone marrow that resembled sarcomatoid carcinoma. The neoplastic cells in bone marrow biopsy specimens formed cohesive-appearing clusters and cords separated by an immature fibroblastic proliferation and myxoid stroma. Blasts in the bone marrow aspirate smears formed clusters and sheets, and a subset of blasts exhibited erythrophagocytosis. Dysgranulopoiesis was also present. Lineage was confirmed by immunohistochemical analysis of formalin-fixed, paraffin-embedded tissue. The tumor cells showed strong reactivity for lysozyme, myeloperoxidase, CD45, and CD68 and were negative for keratin, S100, CD20, and CD3. The serum lysozyme concentration (110 microgram/mL) was 13 times greater than the normal value (8 microgram/mL). Cytogenetic studies performed on bone marrow aspirate material revealed a complex karyotype, including trisomy 8 and abnormalities of chromosome 11q. We report this case of acute myelomonocytic leukemia because the neoplastic cells appeared cohesive and spindled, resembling sarcomatoid carcinoma, and therefore caused diagnostic difficulty. Other monocytic neoplasms with similar resemblance to carcinoma or sarcoma have been reported in the literature, suggesting that the tendency to appear cohesive may be an inherent characteristic of neoplastic cells with monocytic differentiation.
Hamoudi
W H
WH
Division of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Medeiros
L J
LJ
Townsend
G
G
Glassman
A B
AB
Bueso-Ramos
C E
CE
D014408:Biomarkers, Tumor / Q000378:metabolism; D001853:Bone Marrow / Q000378:metabolism / Q000473:pathology; D019046:Bone Marrow Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D002296:Carcinosarcoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D003561:Cytarabine / Q000627:therapeutic use; D003582:Cytogenetics; D003937:Diagnosis, Differential; D017809:Fatal Outcome; D006801:Humans; D015255:Idarubicin / Q000627:therapeutic use; D007150:Immunohistochemistry; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009113:Muramidase / Q000097:blood
D014408:Biomarkers, Tumor; D003561:Cytarabine; D009113:Muramidase; D015255:Idarubicin